cardiac events

Benefits of ultrasound contrast agents outweigh potential risk to heart patients

harminka — Tue, 01 Apr 2008 12:05:32 -0500

A Saint Louis University cardiologist called upon the U.S. Food and Drug Administration (FDA) on Monday to reconsider a strong warning it recently placed on a diagnostic tool, stating that the warning could prevent doctors from detecting life-threatening cardiac events.

Benefits of ultrasound contrast agents outweigh potential risk to heart patients

harminka — Tue, 01 Apr 2008 12:05:32 -0500

Comparison of anticoagulants for angioplasty show similar outcomes

harminka — Mon, 31 Mar 2008 03:26:12 -0500

In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents, according to a JAMA study being released early online March 30.

Penn researchers lead national efforts to improve CPR quality

harminka — Tue, 15 Jan 2008 06:57:34 -0600

“Anyone can save a life.” That’s the message from physicians at the University of Pennsylvania School of Medicine.

Mitochondria send death signal to cardiac cells

harminka — Fri, 09 Nov 2007 08:05:50 -0600

Scientists have determined how cardiac cells die just as emergency treatments restore blood flow to a heart in distress, a paradox that has long puzzled doctors who are able to relieve pain in patients suffering from blocked arteries but can't stop the damage caused by the renewed rush of blood.

AMIHOT II trial data presented at TCT

harminka — Wed, 24 Oct 2007 13:53:55 -0500

Study reveals that the use of oxygen-saturated blood reduces levels of damaged heart tissue following a heart attack

Fewer adverse cardiac events at one year

harminka — Wed, 24 Oct 2007 13:43:40 -0500

Late breaking results from the SPIRIT III trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that after 12 months, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent.